Beta Drugs Limited Stock Price Today (NSE: BETA)
Fundamental Score
Beta Drugs Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Beta Drugs Limited share price today is ₹2287.20, down 2.88% on NSE/BSE as of 25 August 2026. Beta Drugs Limited (BETA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.34K (Cr). The 52-week high for BETA share price is ₹2519.90 and the 52-week low is ₹21.37.
Beta Drugs Limited Share Price Chart — NSE/BSE Historical Performance
Beta Drugs Limited share price chart: 0.00% return over the past month. 52-week high ₹2519.90, 52-week low ₹21.37.
Beta Drugs Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹22.25 | ₹22.43 | ₹21.46 | ₹21.95 | 16.99L (Cr) | |
| ₹22.04 | ₹23.03 | ₹21.37 | ₹21.74 | 17.09L (Cr) | |
| ₹2307.00 | ₹2319.50 | ₹2251.00 | ₹2287.20 | 9.98K (Cr) | |
| ₹2435.00 | ₹2519.90 | ₹2326.20 | ₹2355.00 | 51.81K (Cr) | |
| ₹1615.00 | ₹1681.00 | ₹1602.10 | ₹1661.10 | 7.88K (Cr) | |
| ₹1642.00 | ₹1688.70 | ₹1642.00 | ₹1653.00 | 2.73K (Cr) | |
| ₹1664.00 | ₹1670.00 | ₹1529.00 | ₹1654.00 | 4.72K (Cr) | |
| ₹1689.95 | ₹1689.95 | ₹1652.05 | ₹1666.05 | 3.15K (Cr) | |
| ₹1685.90 | ₹1696.00 | ₹1650.35 | ₹1675.25 | 1.89L (Cr) | |
| ₹1680.00 | ₹1680.00 | ₹1662.55 | ₹1676.50 | 2.42K (Cr) |
Beta Drugs Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2435.00 | ₹2519.90 | ₹21.37 | ₹21.95 | -99.10% | |
| ₹1815.00 | ₹1815.00 | ₹1529.00 | ₹1661.10 | -8.48% | |
| ₹1848.00 | ₹1895.00 | ₹1701.00 | ₹1871.55 | +1.27% | |
| ₹1864.65 | ₹1934.95 | ₹1770.10 | ₹1819.75 | -2.41% |
AI Research Briefing
Powered by Gemini · 2026-08-01
Massive $3.9B backlog backs the vision, but $350M+ annual cash burn requires absolute execution on FAA certification.
WHAT'S HAPPENING NOW (last 2-4 weeks)
BETA Technologies ended its Defense Security Control Agreement on July 22, 2026, following a foreign board member exit. Ahead of its scheduled Q2 2026 earnings release on August 12, 2026, the company recently reiterated full-year 2026 revenue guidance of $39M-$43M while maintaining an expected Adjusted EBITDA loss of $305M-$395M. Q1 2026 revenue stood at $10.1M (up 6% YoY) against a net loss of $122.3M. Commercial backlog reached $3.9B across 991 aircraft.
CORE STORY (THE REAL GAME)
This is an eVTOL certification and commercial ramp-up trade disguised under a local ticker classification. The market is not paying for current revenue; it is betting on FAA type certification of the H500A electric engine and execution on its $3.9B order backlog across defense and commercial logistics.
- Q2 2026 earnings and operational update locked for August 12, 2026.
- Termination of Defense Security Control Agreement on July 22, 2026 following foreign board exit.
- DII stake surged 4.11% while FII stake rose 1.81% over recent period.
- Q2 2026 revenue and cash burn print on August 12, 2026.
- FAA type certification progress on H500A electric engine.
- Conversion of aircraft option backlog ($3.9B total) into firm cash orders.
- Severe ongoing cash burn with 5Y Free Cash Flow at just ₹17.77 Cr against elevated capital needs.
- Q1 2026 net loss of $122.3M on a revenue base of only $10.1M.
- Rich valuation with P/E of 56.33x versus Industry P/E of 34.89x while core operations remain loss-making.
Promoter reduced 0.27% to 64.63%, while institutional buyers stepped in: FII up 1.81% to 2.95% and DII up 4.11% to 6.01%.
Aerospace electrification tailwinds offset by high interest rate overhang on loss-making growth assets.
$3.9 billion commercial backlog across 991 aircraft; added over $375 million in Q1 2026 alone.
No — 5Y Free Cash Flow of ₹17.77 Cr reflects extremely low cash conversion relative to accounting profits.
Binary 3-6 month trajectory hinged on FAA certification progress and Q2/Q3 operational cash burn control. High volatility expected surrounding August 12 earnings report.
Primary Thesis Risk
Regulatory delays or cash burn acceleration forcing dilutive equity capital raises.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Beta Drugs Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Beta Drugs Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BETA across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Excellent ROCE Performance (19.33%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (21.40%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Healthy Liquidity Position (Current Ratio: 3.10)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (66.73%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
High Price-to-Book Ratio (9.55x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Limited Institutional Interest (FII+DII: 8.96%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Beta Drugs Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Beta Drugs Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
52.1/100 | ₹2287.20₹2287 | ₹2336.55₹2336.55 | — — | — — | 19.33%Good 19.33% Good | 0.60Good 0.6 Good | — — | — — | 0.00% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1875.10₹1875 | ₹468821.49₹468821.49 | 38.76Average 38.8 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹8588.00₹8588 | ₹193163.97₹193163.97 | 66.04Average 66.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4971.00₹4971 | ₹169902.02₹169902.02 | 77.90Average 77.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1431.10₹1431 | ₹116131.81₹116131.81 | 34.45Average 34.5 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1115.60₹1116 | ₹115375.77₹115375.77 | 25.57Average 25.6 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2232.00₹2232 | ₹113976.53₹113976.53 | 20.62Average 20.6 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2380.00₹2380 | ₹105053.91₹105053.91 | 51.28Average 51.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | — — | — — | 0.04% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1178.80₹1179 | ₹102660.46₹102660.46 | 31.86Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1645.00₹1645 | ₹90035.87₹90035.87 | 24.25Average 24.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1814.00₹1814 | ₹84016.75₹84016.75 | 76.84Average 76.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | — — | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price468821.49 Cr
- Divi's Laboratories Limited share price193163.97 Cr
- Torrent Pharmaceuticals Limited share price169902.02 Cr
- Cipla Limited share price116131.81 Cr
- Zydus Lifesciences Limited share price115375.77 Cr
Beta Drugs Limited PE Ratio History
Historical price-to-earnings ratio for BETA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹36.10 | ₹2009.00 | 55.7x |
| FY 2023 | ₹30.43 | ₹1470.00 | 48.3x |
| FY 2022 | ₹24.59 | ₹710.00 | 28.9x |
| FY 2021 | ₹11.62 | ₹640.25 | 55.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Beta Drugs Limited Quarterly Performance
Latest quarterly metrics for BETA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
N/A
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Beta Drugs Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BETA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Beta Drugs Limited Financial Statements
Annual income statement, balance sheet and cash flow for Beta Drugs Limited (BETA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Beta Drugs Limited
About BETA (Beta Drugs Limited)
Beta Drugs Limited (BETA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current... market capitalisation of ₹2.34K (Cr). The debt-to-equity ratio stands at 0.60, reflecting the company's capital structure. Investors tracking BETA share price can monitor key metrics including P/E ratio, promoter holding of 66.73%, and quarterly earnings growth.
Company Details
BETA Share Price: Frequently Asked Questions
What is the current share price of Beta Drugs Limited?
Beta Drugs Limited (BETA) trades at ₹2287.20 on NSE. Market cap ₹2.34K (Cr). Educational data only.
What is the P/E ratio of Beta Drugs Limited?
Beta Drugs Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Beta Drugs Limited?
Beta Drugs Limited has a Bull Run score of 52.1/100 based on 25+ financial parameters.
Does Beta Drugs Limited pay dividends?
Beta Drugs Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Beta Drugs Limited?
Beta Drugs Limited has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Beta Drugs Limited?
Beta Drugs Limited has debt-to-equity of 0.60.
Is Beta Drugs Limited a good investment?
Bull Run gives Beta Drugs Limited a score of 52.1/100. This is not investment advice — consult a SEBI-registered advisor.